

RESEARCH

Open Access



# A powerful qPCR-high resolution melting assay with taqman probe in *plasmodium* species differentiation

Aline Lamien-Meda<sup>1\*</sup>, Hans-Peter Fuehrer<sup>2</sup>, David Leitsch<sup>1</sup> and Harald Noedl<sup>3</sup>

## Abstract

**Background:** The use of highly sensitive molecular tools in malaria diagnosis is currently largely restricted to research and epidemiological settings, but will ultimately be essential during elimination and potentially eradication. Accurate diagnosis and differentiation down to species levels, including the two *Plasmodium ovale* species and zoonotic variants of the disease, will be important for the understanding of changing epidemiological patterns of the disease.

**Methods:** A qPCR-high resolution melting (HRM) method was to detect and differentiate all human *Plasmodium* species with one forward and one reverse primer set. The HRM detection method was further refined using a hydrolysis probe to specifically discriminate *Plasmodium falciparum*.

**Results:** Out of the 113 samples tested with the developed HRM-qPCR- *P. falciparum* probe assay, 96 (85.0%) single infections, 12 (10.6%) mixed infections, and 5 (4.4%) were *Plasmodium* negative. The results were concordant with those of the nested PCR at 98.2%. The assay limit of detection was varied from 21.47 to 46.43 copies / $\mu$ l, equivalent to 1–2.11 parasites/ $\mu$ l. All *P. falciparum* infections were confirmed with the associated Taqman probe.

**Conclusions:** Although the dependence on qPCR currently limits its deployment in resource-limited environments, this assay is highly sensitive and specific, easy to perform and convenient for *Plasmodium* mono-infection and may provide a novel tool for rapid and accurate malaria diagnosis also in epidemiological studies.

**Keywords:** Malaria, qPCR, HRM, *Plasmodium*, *Plasmodium falciparum*, *Plasmodium ovale wallikeri*, *Plasmodium ovale curtisi*, *Plasmodium vivax*, *Plasmodium knowlesi*, *Plasmodium malariae*

## Background

A significant step-up in worldwide malaria control efforts in the past decades has resulted in a considerable reduction of mortality and clinical episodes in many malaria-endemic countries [1]. At the same time, asymptomatic infections have gained importance as a reservoir of new infections and epidemics. Novel and more sensitive tools are, therefore, urgently needed to support when technically possible, microscopic examination of thick and thin

bloods films remaining the gold standard for laboratory diagnosis of malaria in resource-limited environments.

In Europe and European Economic Area, 8349 malaria cases were reported in 2018 and nearly all reported cases were imported. Around 84% of imported malaria cases have been reported to be non-falciparum malaria [2]. These tend to receive limited attention due to their less severe clinical course (when compared to *Plasmodium falciparum*); however, recent and increasing numbers of studies are supporting the capacity of *Plasmodium vivax* to cause severe disease by affecting the spleen, lungs and bone marrow [3–7]. These findings are prompting a more thorough and comprehensive differentiation between

\*Correspondence: Aline.LamienMeda@meduniwien.ac.at

<sup>1</sup> Institute for Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria

Full list of author information is available at the end of the article



species for a correct treatment approach, particularly in regions with declining *Plasmodium* endemicity [8].

In spite of a similar presentation in the early stages of the disease *P. vivax* and *Plasmodium ovale* spp. pose specific challenges due to their ability to produce dormant liver stages (hypnozoites). These can induce re-activation of malaria up to several years after the initial infection [9]. Infection with *Plasmodium malariae*, known as quartan fever, can result in long-lasting disease if not well treated. *Plasmodium ovale* spp. and *P. malariae* were reported to be responsible for asymptomatic cases in a seroprevalence study of *P. ovale* spp. and *P. malariae* in healthy populations in Western Africa [10].

The *Plasmodium* mitochondrial genome (6-kb) is rooted entirely from the female gametocyte and does not undergo recombination among lineages. That makes it a desirable candidate for pathogens surveillance and for *Plasmodium* species diagnosis. Additionally, the mitochondrial genome exists in multiple copies (up to ~22 copies) defining it as a good target for *Plasmodium* species differentiation [11–16].

Light microscopy and immuno-chromatographic rapid diagnostic tests (RDTs) are the two methods recommended by the World Health Organization (WHO) and used routinely for parasitological diagnosis of malaria [17]. However, particularly in asymptomatic infections and in the case of low parasite densities, misclassification and low detection rates of non-falciparum malaria are commonly reported with microscopy and RDTs, respectively [18]. Multiplex qPCR has been identified as a substantial improvement to microscopy in reference to laboratory detection of malaria species specifically due to its superior limit of detection (LOD) [18].

Since the development of PCR based methods in malaria diagnosis in the late 1980s, several methods targeting the *Plasmodium* 18S SSU RNA gene have been developed. These methods include isothermal amplification (LAMP), conventional nested and semi-nested PCRs, and real-time PCRs [19, 20]. However, *Plasmodium* species-specific identification by these methods requires multiplexing or many time-consuming steps using primer pairs that are specific to each of the *Plasmodium* species.

High-Resolution Melting (HRM) curve analysis is a fast and straightforward post-PCR analysis which has been successfully applied for genotyping, including pathogen-typing. In this procedure, the region of interest is amplified in the presence of a specialized DNA binding dye and a gradual denaturation of the amplicons, which produce characteristic melting profiles. Recently, an HRM assay targeting the 18S SSU RNA was described for simultaneous detection and typing of five *Plasmodium* species affecting humans [21]. The use of such an HRM

assay would help saving time in *Plasmodium* species identification. HRM technology was successfully used to differentiate both *P. ovale* species in one PCR reaction by targeting the highly conserved apicoplast genome [22].

In this paper, a qPCR high-resolution assay is described targeting the mitochondrial DNA for simultaneous detection and quantification of *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale curtisi*, *P. ovale wallikeri* and *Plasmodium knowlesi*, with high specificity and sensitivity. A Taqman probe was added to the PCR mix to specifically detect and confirm *P. falciparum* infection.

## Methods

### Samples and DNA extraction

Samples (113) from published studies conducted in Bangladesh, Malaysia and Ethiopia were used for method development (Additional file 1). All samples were collected under approved protocols and after obtaining written informed consent. Parasite density and species diagnosis were initially established by microscopy and nested PCR [23, 24]. Archived filter papers of each sample (4 × 4 mm blood spots soaked overnight in 100 µl PBS at 4°C) were used for DNA extraction with Illustra blood genomicPrep Mini Spin kits (GE Healthcare, Buckinghamshire, UK) following the manufacturer's protocol. The DNA was eluted with two times 50 µl of elution buffer and stored at – 20 °C.


### Target selection and primer design

The mitochondrial (complete or partial) genome of *P. falciparum* (KT119883, KT119882), *P. ovale* spp. (AB354571, HQ712052, HQ712053), *P. vivax* (KF668406, AY598121), *P. malariae* (AB489192, AB354570), and *P. knowlesi* (AY598141, AY722797) obtained from GenBank (National Center for Biotechnology Information, Bethesda, MD) were used for primer design.

The selected fragment of all six *Plasmodium* species is presented in Fig. 1. The partial mitochondrial genome was aligned using the clustalW algorithm, as implemented in the BioEdit software package version 7.2.6. After the identification and selection of a specific and conserved region, a pair of primers, specific to all 6 *Plasmodium* species was designed to amplify a 109–117 bp fragment for the real-time PCR-HRM assay (qPCR-HRM) using the Primer3 online tool. The primers were synthesized by Eurofins MWG Synthesis GmbH (Ebersberg, Germany) and purified by reverse-phase high-performance liquid chromatography.

### PCR and melting curve

The PCR reaction was performed in 20 µl containing 100 nM forward primer (PhHRM F1: 5'-CGTCTCATC GCAGCCTTG- 3'), 100 nM reverse primer (PhHRM



R1: 5'-AGGTTAACGCCTGGAGTTCT-3'), 1x GoTaq qPCR master mix (Promega Corporation, Madison, USA), 50 nM of Texas red probe (5' TR-GTCACGCAATATCAATATA-MGB-Eclipse 3') (Eurogentec, Liège, Belgium) and 4 µl DNA sample. The PCR was performed in a Roche LightCycler 480 qPCR system (Roche Diagnostics GmbH, Mannheim, Germany) with an initial denaturation step at 95 °C for 3 min, followed by 45 cycles of 95 °C for 10 sec and 62 °C for 30 sec. The PCR products were then subjected to the following melting programme: denaturation at 95 °C for 1 min, cooling to 65 °C (held for 1 min), and continuous heating at 2.2 °C/s with fluorescence acquisition from 65 °C to 95 °C. Two filter combinations were used: SYBR Green/ HRM dye and 533–610/ Texas-red dye.

#### Positive control plasmids preparation and sequencing

The short fragment of each *Plasmodium* species (Fig. 1) was inserted into TOPO vector using the TOPO<sup>®</sup> TA Cloning<sup>®</sup> Kit, and the recombinant vector was transformed into competent *Escherichia coli*. Selected positive clones were cultured, the plasmids purified and sequenced by Eurofins MWG Synthesis GmbH (Ebersberg, Germany). The sequencing data were analysed using Vector NTI.10 (Invitrogen) software, and the sequences were checked by using the Basic Local Alignment Search Tool (Nucleotide BLAST) to confirm their identity.

#### Assay sensitivity, specificity and precision

The method specificity was evaluated with the melting profile (comparatively to the positive control plasmid), and also with DNA from the following organisms (using identical PCR conditions): *Toxoplasma gondii*, *Leishmania infantum*, *Trypanosoma brucei*, *Trypanosoma cruzi*, *Babesia divergens*, *Entamoeba histolytica*, *Cryptosporidium parvum*, *Giardia intestinalis*, *Enterocytozoon bienersi*, *Encephalitozoon cuniculi*, *Pneumocystis jirovecii*, *Echinococcus granulosus*, *Strongyloides stercoralis*,

*Dirofilaria repens*, *Toxocara canis*, and *Ascaris suum*. Five *Plasmodium* negative blood spots on filter papers from human were tested. The assay was performed in duplicate with each DNA sample.

The PCR amplification efficiency was established by the means of three calibration curves providing the mean PCR efficiency and analytical sensitivity. The PCR efficiency was calculated according to the following formula:


$$\text{PCR efficiency} = 10^{-1/\text{slope}} - 1 \quad [25].$$

The assay sensitivity was expressed as the limit of detection (LOD) at 95% probability. The LOD for each *Plasmodium* species was defined as the measured concentration producing at least 95% positive replicates [26]. The LOD was assessed by amplifying seven different concentrations (80, 60, 40, 20, 10, 8, and 6 copies/µl) of each plasmid in six (6) replicates on four separate occasions. The total proportion of positive tests was recorded and subjected to probit regression analysis using R version 3.4.2 (2017-09-28) via RStudio version Version 1.1.383 to obtain LOD with confidence interval (CI). Similarly, the boxplots of the melting temperatures ( $T_m$ ) were also produced using R via the RStudio version. The Welch's unequal variances t-test was used to compare the difference between arithmetic means of the respective  $T_m$  of the amplicons of all five parasite species using R.

## Results

### Assay design and optimization

Species identification was originally performed by microscopy analysis and/ or nested PCR (Additional file 1). The assay required one forward and one reverse primer binding specifically to all six human *Plasmodium* species (Fig. 1). The melting temperature ( $T_m$ ) values were  $77.25 \pm 0.03$  °C (*P. malariae*),  $77.69 \pm 0.12$  °C (*P. vivax*),  $78.11 \pm 0.06$  °C (*P. knowlesi*),  $78.53 \pm 0.03$  °C (*P. ovale wallikeri*),  $78.73 \pm 0.05$  °C (*P. ovale curtisi*), and  $79.01 \pm 0.12$  °C (*P. falciparum*) (Figs. 2 and 3). The high-resolution melting analysis is differentiating each *Plasmodium* species from the others with a range of



$\Delta T_m$  of 0.20–0.44 °C. Single infections were systematically identified based on their melting temperature described in Table 1.

**Assay performance**

Isolated plasmid construct with each mitochondrial fragment of the *Plasmodium* species was used to determine the efficiency of the assay by amplifying 10-fold serial dilutions starting with  $10^7$  copies/ $\mu$ l to 10 copies/ $\mu$ l. The

**Table 1** Assay melting temperature, specificities, and limits of detection (LOD) with confidence interval (CI)

Species	n	Test	T <sub>m</sub> (T <sub>m</sub> range) (°C)	Efficiency (%)	Slope	R <sup>2</sup>	LOD with CI (Copy/ $\mu$ l)
<i>P. malariae</i>	3	HRM	77.25 ± 0.03 (77.20–77.28)	99.85	− 3.3256	0.9974	21.47 (15.97–41.16)
<i>P. vivax</i>	33	HRM	77.69 ± 0.12 (77.50–77.94)	98.78	− 3.3527	0.9985	29.36 (22.61–45.85)
<i>P. knowlesi</i>	5	HRM	78.11 ± 0.06 (78.06–78.22)	99.74	− 3.3281	0.9927	42.47 (31.67–67.57)
<i>P. ovale wallikeri</i>	13	HRM	78.53 ± 0.03 (78.45–78.57)	94.99	− 3.4482	0.9992	33.47 (24.49–57.87)
<i>P. ovale curtisi</i>	5	HRM	78.73 ± 0.05 (78.65–78.79)	97.67	− 3.3791	0.9985	30.26 (22.68–49.81)
<i>P. falciparum</i>	38	HRM	79.01 ± 0.12 (78.80–79.23)	97.95	− 3.3720	0.9991	46.43 (32.50–85.44)
<i>P. falciparum</i>	38	Probe	–	97.18	− 3.3913	0.9988	–

ranges of efficiency, slope, and  $R^2$  were 94.99 to 99.85%,  $-3.3256$  to  $-3.4482$ , and 0.9927 to 0.9992, respectively (Table 1). The probit analysis of runs between 80 and 10 copies / $\mu\text{l}$  provided LODs at 95% confidence varying from 21.47 (15.97–41.16) copies / $\mu\text{l}$  with *P. malariae* to 46.43 (32.50–85.44) copies / $\mu\text{l}$  with *P. falciparum* (Table 1).


The discrimination power of the assay was tested using 108 *Plasmodium* positive samples, 5 *Plasmodium* negative samples, and also DNA samples positive for 16 other organisms listed in section material and methods. The melting temperature ( $T_m$ ) results of the *Plasmodium* samples are illustrated in boxplots (Fig. 3). The Welch's unequal variances t-test showed that  $T_m$  of all *Plasmodium* amplicon (6) was significantly different ( $p$ -value  $< 2.2e-16$ ).

Out of the 113 samples tested with the HRM-qPCR-*P. falciparum* probe assay, 96 (85.0%) single infections were detected: 11 *P. malariae*, 5 *P. knowlesi*, 6 *P. ovale curtisi*, 8 *P. ovale wallikeri*, 31 *P. vivax* and 35 *P. falciparum* were detected (Fig. 4). Additionally, 12 (10.6%) mixed infections of *P. malariae* / *P. falciparum* (2), *P. falciparum* / *P. ovale curtisi* (2), *P. vivax* / *P. falciparum* (5), and *P. falciparum* / *P. ovale wallikeri* (3), were identified. Five (4.4%) samples were *Plasmodium* negative. All mix infections were observed with *P. falciparum* infection confirmed by high resolution melting and/or by the probe with texas-red detection at 650nm. The HRM melting curves alone allowed the detection of two of the four mixed infections (*P. falciparum* / *P. malariae*, and *P. falciparum* / *P. vivax*) (Fig. 5) confirmed by the Taqman probe amplification curve. The two additional mixed infections *P. falciparum* / *P. ovale curtisi*, and *P. falciparum* / *P. ovale wallikeri* needed both HRM  $T_m$  (for *P. ovale* species) and Taqman probe amplification (for *P. falciparum*) to be confirmed.


The results were concordant with those of the nested PCR at 98.2% at 95% CIs. Indeed, out of the 113 samples, two mixed infections of *P. falciparum* / *P. ovale curtisi* (nested PCR) were detected as single infections with *P. falciparum* using the qPCR-HRM-*P. falciparum* probe assay. The selected forward and reverse primers were specifically binding to all six *Plasmodium* species and did not amplify any of the 16 organisms used to test the specificity of the method.

## Discussion


A combination of an intercalating dye with a hydrolysis probe real-time PCR is described with a simultaneous differentiation of all human *Plasmodium* species. The hydrolysis probe designed for *P. falciparum* was included to double differentiate the predominant and potentially most virulent parasite (*P. falciparum*) from the other *Plasmodium* species: *P. ovale wallikeri*, *P.*



*ovale curtisi*, *P. vivax*, *P. malariae*, and *P. knowlesi*. In an attempt to increase the assay specificity and sensitivity, the mitochondrial genome was targeted because it is more conserved within each of the *Plasmodium* species and exists in multiple copies (up to ~22 copies) within each parasite [13–16]. The developed assay's specificity (98.2% at 95% CIs) and sensitivity (LODs of 21.47–46.43 copies/ $\mu\text{l}$ , equivalent to 1–2.11 parasites/ $\mu\text{l}$ ) are comparable to those of other studies like Joste et al. [27] and Murillo et al. [28] with 100% specificity and 1 parasite/ $\mu\text{l}$  sensitivity. Chua et al. [21] reported a sensitivity range of 1–100 copies/ $\mu\text{l}$  in a qPCR-HRM assay targeting the 18S SSU rRNA gene of *Plasmodium* spp. with also one primer set. Similar LODs values of 1 parasite/ $\mu\text{l}$  and 1–10 parasites/ $\mu\text{l}$  were also achieved by Lucchi et al. [29] and Demas et al. [30] with *P. knowlesi*, and *P. falciparum*-*P. vivax*, respectively. Further studies have shown that lower LODs can be achieved when the qPCR target has higher copy number like the telomeric-associated repetitive element 2 (TARE-2, ~250 copies/genome) and the *var* gene acidic terminal sequence (varATS, 59 copies/genome). Indeed, lower LODs (0.03–0.15 parasites/ $\mu\text{l}$ ) were achieved by Hofmann et al. [31] using the TARE-2 and varATS, respectively for *P. falciparum* and *P. vivax*. More recently, Gupta et al. [32] reported 34–44 copies of PfMLS152 and PvMLS110 sequences corresponding to *P. falciparum* and *P. vivax*, respectively, with a low LOD value (0.1 parasites/ $\mu\text{l}$ ). The qPCR assay also demonstrated the



**Fig. 4** qPCR-HRM (azure blue) results of 113 samples compared to nested PCR (baby blue). The qPCR-HRM results of 113 (98%) samples matched with the nested PCR. Two mixed infections of *P. falciparum*/*P. ovale curtisi* were detected as a single infection of *P. falciparum* in the developed qPCR-HRM assay



**Fig. 5** Melting peaks of mixed infection samples presenting 2 cases of double infection: **a** *P. malariae* (grey), *P. falciparum* (red) with a mixed infection *P. malariae*/*P. falciparum* (black). **b** *P. vivax* (pink), *P. falciparum* (red) with a mixed infection *P. vivax*/*P. falciparum* (grey)

utility of multi-copy DNA sequence in the diagnosis of malaria. Its sensitivity is lower compare to other studies but the developed assay is presenting the advantage to target a conserved fragment of the mitochondria genome compare to the poor homology of the repeats

in assays with higher copy of genomic sequences [31, 32].

The time needed to run a sample, including both amplification curves detection and melting curve analysis, was 1h15 min without a probe, and 2 h when the

Texas-red probe was added, respectively. The qPCR-HRM developed by Chua et al. [21] was also performed in 2 hours. These single PCR techniques are faster compared to the conventional approaches based on nested PCR with additional PCR product separation by electrophoresis in agarose gel [23, 33, 34].

This assay has the advantage of detecting all *Plasmodium* species with a single primer set in one PCR reaction. Additionally, *P. falciparum* infection is confirmed with the hydrolysis probe in the same PCR reaction. Mixed infections remain a major challenge even for experienced microscopists and are difficult to detect with most currently available RDTs. Such a method will therefore be essential in co-endemic areas where species differentiation is crucial for directing appropriate treatment and surveillance [17]. This assay provides a sensitive and rapid method to overcome the difficulties with distinguishing mixed infections involving *P. falciparum*, e.g., *P. knowlesi*/*P. falciparum* [35], or *P. malariae*/*P. falciparum* [36].

A limitation of the current assay is the identification of selected mixed infections due to the small  $T_m$  difference between the species. Indeed, mixed infections involving the two *P. ovale* species (*walikeri* and *curtisi*) would be detected as a single infection with the developed assay. This, however, has very limited clinical implications. In this case, a method targeting the two closely related *P. ovale* species like the one previously developed [22], are necessary to differentiate the species.

The use of a Taqman probe (250 \$ for ~6000 qPCR reactions) was generating additional cost making the developed assay slightly more expensive than the SYBR Green detection assays [21]. But the probe cost is distributed across thousands of PCR reactions making low impact on the cost of sample analysis. Despite using a Taqman probe, the developed assay remains cost-efficient compared to a fluorescence resonance energy transfer (FRET) more expensive than the Taqman probes [37–39]. The assay without the Taqman probe will indeed identify any *Plasmodium* infection through the specific melting temperature.

## Conclusions

This is the first method describing the combination of non-probe (HRM) with a hydrolysis probe qPCR in malaria diagnosis. The assay is targeting all six *Plasmodium* species with an additional detection step for *P. falciparum* infection. The assay provides a highly sensitive, specific, and easy to perform HRM-hydrolysis probe qPCR assay for differentiating and quantifying malaria parasites. This qPCR assay could contribute to a timely diagnosis in both non-malaria-endemic and malaria-endemic areas and also contribute to protecting the most

vulnerable population groups, like young children and non-immune populations, in whom *P. falciparum* can be rapidly fatal.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12936-021-03662-w>.

**Additional file 1: Table S1.** List of samples used to evaluate the developed qPCR-HRM assay with their microscopy, nested PCR, and qPCR-HRM genotyping.

### Abbreviations

BLAST: Basic local alignment search tool; DNA: Deoxyribonucleic acid; FRET: Fluorescence resonance energy transfer; HRM: High resolution melting; LOD: Limit of detection; PCR: Polymerase chain reaction;  $T_m$ : Melting temperature; TARE: Telomeric-associated repetitive element 2; varATS: Var gene acidic terminal sequence; PfMLS152: *Plasmodium falciparum* multiloci short stretch of 152; PvMLS110: *Plasmodium vivax* multiloci short stretch of 110.

### Acknowledgements

Not applicable.

### Authors' contributions

ALM developed the qPCR-HRM with Taqman probe assay, analysed data and wrote the manuscript. H-PF contributed to the data analysis and to the manuscript writing. DL coordinated the cloning experiments, discussed the data and co-edited the manuscript. HN contributed to the study design, the study coordination, the overall supervision, the data analysis and manuscript review. All authors read and approved the final manuscript.

### Funding

This study was supported by Malaria Research Initiative Bandarban, Vienna, Austria.

### Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### Ethics approval and consent to participate

All study protocols have been approved by the corresponding ethical review boards and written informed consent was obtained from all study participants.

### Consent for publication

All samples were collected under approved protocols and after obtaining written informed consent.

### Competing interests

The authors declare that they have no competing interests.

### Author details

<sup>1</sup> Institute for Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria. <sup>2</sup> Institute of Parasitology, University of Veterinary Medicine, Vienna, Austria. <sup>3</sup> Malaria Research Initiative Bandarban, Vienna, Austria.

Received: 4 January 2021 Accepted: 20 February 2021

Published online: 28 February 2021

## References

1. Tanner M, Greenwood B, Whitty CJM, Ansah EK, Price RN, Dondorp AM, et al. Malaria eradication and elimination: views on how to translate a vision into reality. *BMC Med*. 2015;13:167.

2. European Centre for Disease Prevention and Control. Malaria - Annual Epidemiological Report for 2018. Stockholm: ECDC; 2020.
3. Anvikar AR, van Eijk AM, Shah A, Upadhyay KJ, Sullivan SA, Patel AJ, et al. Clinical and epidemiological characterization of severe *Plasmodium vivax* malaria in Gujarat, India. *Virulence*. 2020;11:730–8.
4. Siqueira AM, Lacerda MV, Magalhães BM, Mourão MP, Melo GC, Alexandre MA, et al. Characterization of *Plasmodium vivax*-associated admissions to reference hospitals in Brazil and India. *BMC Med*. 2015;13:57.
5. Machado Siqueira A, Lopes Magalhães BM, Cardoso Melo G, Ferrer M, Castillo P, Martin-Jaular L, et al. Spleen rupture in a case of untreated *Plasmodium vivax* infection. *PLoS Negl Trop Dis*. 2012;6:e1934.
6. Obaldia N, Meibalan E, Sa JM, Ma S, Clark MA, Mejia P, et al. Bone marrow is a major parasite reservoir in *Plasmodium vivax* infection. *MBio*. 2018;9:e00625-18.
7. Anstey NM, Handojo T, Pain MCF, Kenangalem E, Tjitra E, Price RN, et al. Lung injury in vivax malaria: pathophysiological evidence for pulmonary vascular sequestration and post treatment alveolar-capillary inflammation. *J Infect Dis*. 2007;195:589–96.
8. Ruas R, Pinto A, Nuak J, Sarmento A, Abreu C. Non-falciparum malaria imported mainly from Africa: a review from a Portuguese hospital. *Malar J*. 2017;16:298.
9. Richter J, Franken G, Mehlhorn H, Labisch A, Häussinger D. What is the evidence for the existence of *Plasmodium ovale* hypnozoites? *Parasitol Res*. 2010;107:1285–90.
10. Doderer-Lang C, Atchade PS, Meckert L, Haar E, Perrotey S, Filisetti D, et al. The ears of the African elephant: Unexpected high seroprevalence of *Plasmodium ovale* and *Plasmodium malariae* in healthy populations in Western Africa. *Malar J*. 2014;13:240.
11. Conway DJ, Fanello C, Lloyd JM, Al-Joubori BMAS, Baloch AH, Somanath SD, et al. Origin of *Plasmodium falciparum* malaria is traced by mitochondrial DNA. *Mol Biochem Parasitol*. 2000;111:163–71.
12. Haanshuus CG, Mohn SC, Mørch K, Langeland N, Blomberg B, Hanevik K. A novel, single-amplification PCR targeting mitochondrial genome highly sensitive and specific in diagnosing malaria among returned travellers in Bergen, Norway. *Malar J*. 2013;12:26.
13. Krungkrai J. The multiple roles of the mitochondrion of the malarial parasite. *Parasitology*. 2004;129:511–24.
14. Preiser PR, Wilson RJM, Moore PW, McCreedy S, Hajibagheri MAN, Blight KJ, et al. Recombination associated with replication of malarial mitochondrial DNA. *EMBO J*. 1996;15:684–93.
15. Preston MD, Campino S, Assefa SA, Echeverry DF, Ocholla H, Amambua-Ngwa A, et al. A barcode of organellar genome polymorphisms identifies the geographic origin of *Plasmodium falciparum* strains. *Nat Commun*. 2014;5:4052.
16. Schmedes SE, Patel D, Kelley J, Udhayakumar V, Talundzic E. Using the *Plasmodium* mitochondrial genome for classifying mixed-species infections and inferring the geographical origin of *P. falciparum* parasites imported to the U.S. *PLoS One*. 2019;14:e0215754.
17. WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015. p.MID: 26020088.
18. Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR. Multiplex real-time quantitative PCR, microscopy and rapid diagnostic immuno-chromatographic tests for the detection of *Plasmodium spp*: Performance, limit of detection analysis and quality assurance. *Malar J*. 2009;8:284.
19. Fuehrer HP, Noedl H. Recent advances in detection of *Plasmodium ovale*: Implications of separation into the two species *Plasmodium ovale wallikeri* and *Plasmodium ovale curtisi*. *J Clin Microbiol*. 2014;52:387–91.
20. Alemayehu S, Feghali KC, Cowden J, Komisar J, Ockenhouse CF, Kamau E. Comparative evaluation of published real-time PCR assays for the detection of malaria following MIQE guidelines. *Malar J*. 2013;12:277.
21. Chua KH, Lim SC, Ng CC, Lee PC, Lim YAL, Lau TP, et al. Development of high resolution melting analysis for the diagnosis of human malaria. *Sci Rep*. 2015;5:1674.
22. Lamien-Meda A, Fuehrer H-P, Noedl H. H. Novel high resolution melting (HRM) and snapback assays for simultaneous detection and differentiation of *Plasmodium ovale spp*. *Acta Trop*. 2019;192:75–81.
23. Fuehrer HP, Habler VE, Fally MA, Harl J, Starzengruber P, Swoboda P, et al. *Plasmodium ovale* in Bangladesh: Genetic diversity and the first known evidence of the sympatric distribution of *Plasmodium ovale curtisi* and *Plasmodium ovale wallikeri* in southern Asia. *Int J Parasitol*. 2012;42:693–9.
24. Alemu A, Fuehrer H-P, Getnet G, Tessema B, Noedl H. *Plasmodium ovale curtisi* and *Plasmodium ovale wallikeri* in North-West Ethiopia. *Malar J*. 2013;12:346.
25. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. *Clin Chem*. 2009;55:611–22.
26. Forootan A, Sjöback R, Björkman J, Sjögreen B, Linz L, Kubista M. Methods to determine limit of detection and limit of quantification in quantitative real-time PCR (qPCR). *Biomol Detect Quantif*. 2017;12:1–6.
27. Joste V, Kamaliddin C, Kendjo E, Hubert V, Argy N, Houzé S. Distinction of *Plasmodium ovale wallikeri* and *Plasmodium ovale curtisi* using quantitative polymerase chain reaction with high resolution melting revelation. *Sci Rep*. 2018;8:300.
28. Murillo E, Muskus C, Agudelo LA, Vélez ID, Ruiz-Lopez F. A new high-resolution melting analysis for the detection and identification of *Plasmodium* in human and *Anopheles* vectors of malaria. *Sci Rep*. 2019;9:1674.
29. Lucchi NW, Poorak M, Oberstaller J, DeBarry J, Srinivasamoorthy G, Goldman I, et al. A new single-step PCR assay for the detection of the zoonotic malaria parasite *Plasmodium knowlesi*. *PLoS One*. 2012;7:e31848.
30. Demas A, Oberstaller J, DeBarry J, Lucchi NW, Srinivasamoorthy G, Sumari D, et al. Applied genomics: data mining reveals species-specific malaria diagnostic targets more sensitive than 18S rRNA. *J Clin Microbiol*. 2011;49:2411–8.
31. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive detection of *Plasmodium falciparum* by amplification of multi-copy subtelomeric targets. *PLoS Med*. 2015;12:e1001788.
32. Gupta H, Srivastava S, Chaudhari S, Vasudevan TG, Hande MH, D'souza SC, et al. New molecular detection methods of malaria parasites with multiple genes from genomes. *Acta Trop*. 2016;160:15–22.
33. Snounou G, Viriyakosol S, Jarra W, Thaithong S, Brown KN. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. *Mol Biochem Parasitol*. 1993;58:283–92.
34. Mfuh KO, Achonduh-Atijegbe OA, Bekindaka ON, Esemu LF, Mbakop CD, Gandhi K, et al. A comparison of thick-film microscopy, rapid diagnostic test, and polymerase chain reaction for accurate diagnosis of *Plasmodium falciparum* malaria. *Malar J*. 2019;18:73.
35. Lee K-S, Cox-Singh J, Singh B. Morphological features and differential counts of *Plasmodium knowlesi* parasites in naturally acquired human infections. *Malar J*. 2009;8:73.
36. Cox-Singh J, Davis TME, Lee K-S, Shamsul SSG, Matusop A, Ratnam S, et al. *Plasmodium knowlesi* malaria in humans is widely distributed and potentially life threatening. *Clin Infect Dis*. 2008;46:165–71.
37. Rougemont M, Saanen M, Van, Sahli R, Hinrikson HP, Bille J, Jaton K. Detection of four *Plasmodium* species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays. *J Clin Microbiol*. 2004;42:5636–43.
38. Ojurongbe O, Ogungbamigbe TO, Fagbenro-Beyioku AF, Fendel R, Krensner PG, Fj Kun J. Rapid detection of Pfcrt and Pfmdr1 mutations in *Plasmodium falciparum* isolates by FRET and in vivo response to chloroquine among children from Osogbo, Nigeria. *Malar J*. 2007;6:41.
39. Kutayin IV. Use of extremely short Förster resonance energy transfer probes in real-time polymerase chain reaction. *Nucleic Acids Res*. 2013;41:e191.

## Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.